TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of “Hold” from Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have received a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.60.

Several equities research analysts recently weighed in on TCRX shares. Morgan Stanley lowered TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a report on Friday, November 14th. BTIG Research downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. Needham & Company LLC lowered their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. HC Wainwright cut their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Thursday, January 22nd.

Insider Activity at TScan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of TScan Therapeutics stock in a transaction dated Friday, December 19th. The stock was bought at an average cost of $0.90 per share, for a total transaction of $72,062.10. Following the completion of the transaction, the insider owned 7,937,416 shares in the company, valued at $7,143,674.40. This trade represents a 1.02% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired 161,801 shares of company stock valued at $145,621 over the last three months. 4.35% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TCRX. Boothbay Fund Management LLC increased its stake in TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after acquiring an additional 8,121 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after acquiring an additional 9,676 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in shares of TScan Therapeutics during the second quarter worth about $26,000. Letko Brosseau & Associates Inc. increased its position in shares of TScan Therapeutics by 24.4% in the second quarter. Letko Brosseau & Associates Inc. now owns 95,875 shares of the company’s stock worth $139,000 after purchasing an additional 18,775 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of TScan Therapeutics in the second quarter worth approximately $29,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $1.11 on Thursday. The company has a market capitalization of $62.99 million, a P/E ratio of -0.99 and a beta of 1.04. The business has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $1.42. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44. TScan Therapeutics has a 1 year low of $0.88 and a 1 year high of $2.57.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.